Press Release | Association for Accessible Medicines

White Paper: Ensuring the Future of Accessible Medicines in the US

Feb 12, 2018 | Rachel Schwartz

White Paper: Ensuring the Future of Accessible Medicines in the U.S.

Feb 12, 2018 | Rachel Schwartz

AAM Announces 2018 Board of Directors

Feb 6, 2018 | Rachel Schwartz

AAM and the Biosimilars Council Call on Congress to Increase Patient Access to Biosimilars

AAM Calls to FTC Action to Ensure Generic Drugs for Patients

Dec 11, 2017 | Rachel Schwartz

AAM Calls for FTC Action to Ensure U.S. Supply of Generic Drugs for Patients

EverFi Prescription Drug Safety Program - Roundtable

Nov 16, 2017 | Rachel Schwartz

AAM Launches National Prescription Safety Program on College and University Campuses

EVERFI - National Prescription Safety Program

Nov 14, 2017 | Rachel Schwartz

AAM to Launch National Prescription Safety Program on College and University Campuses

Nov 6, 2017 | Rachel Schwartz

AAM Continues to Build Its State Government Affairs Team

AAM - Your Generics & Biosimilars Industry

Oct 31, 2017 | Rachel Schwartz

AAM Statement on Considered Expansion of Antitrust Lawsuit Against Generic Drugmakers

SB 17 Signed Into Law

Oct 10, 2017 | Rachel Schwartz

California SB 17 Signed Into Law

Ruling HB 631

Sep 29, 2017 | Rachel Schwartz

AAM Statement on Federal District Court Ruling on HB 631

Sep 19, 2017 | Rachel Schwartz

New Report Indicates Revising CMS Policy on Biosimilars Could Save $11.4 Billion On Medicines Over 10 Years

North American Trade Agreement - NAFTA

Sep 19, 2017 | Rachel Schwartz

AAM and Sister Associations in Canada and Mexico: Governments Should Not Raise Drug Prices in Renegotiated NAFTA